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Abstract
Background: Recruitment and retention in clinical trials remains an important challenge, particularly in the context
of advanced disease. It is important to understand what affects retention to improve trial quality, minimise attrition
and reduce missing data. We conducted a qualitative study embedded within a randomised feasibility trial and
explored what influenced people to take part and remain in the trial.
Methods: We conducted a qualitative study embedded within a double-blind randomised trial (BETTER-B[Feasibility]:
BETter TreatmEnts for Refractory Breathlessness) designed using a person-centred approach. Participants with cancer,
chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), or chronic heart failure (CHF), with a
modified Medical Research Council dyspnoea scale grade of 3/4 were recruited from three UK sites. A convenience
subsample completed qualitative interviews after the trial. Interviews were analysed using thematic analysis. Results
were considered in relation to the core elements of person-centred care and our model of the person-centred trial.
Results: In the feasibility trial 409 people were screened for eligibility, and 64 were randomised. No participant was lost
to follow-up. Twenty-two participants took part in a qualitative interview. Eleven had a diagnosis of COPD, 8 ILD, 2 CHF
and 1 lung cancer. The participants’ median age was 71 years (range 56–84). Sixteen were male. Twenty had
completed the trial, and two withdrew due to adverse effects. The relationship between patient and professional,
potential for benefit, trial processes and the intervention all influenced the decision to participate in the trial. The
relationship with the research team and continuity, perceived benefit, and aspects relating to trial processes and the
intervention influenced the decision to remain in the trial.
Conclusions: In this feasibility trial recruitment targets were met, attrition levels were low, and aspects of the person-
centred approach were viewed positively by trial participants. Prioritisation of the relationship between the patient and
professional; person-centred processes, including home visits, assistance with questionnaires, and involvement of the
carer; and enabling people to participate by having processes in line with individual capabilities appear to support
recruitment and retention in clinical trials in advanced disease. We recommend the integration of a person-centred
approach in all clinical trials.
Trial registration: ISRCTN Registry, ISRCTN32236160. Registered on 13 June 2016.
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Background
Recruitment and retention in clinical trials remains an
important challenge which can impact the validity of
results by introducing bias and reducing power. Of 151
randomised controlled trials (RCTs) funded and pub-
lished by the UK’s National Institute for Health Re-
search (NIHR), the target sample size was only achieved
in 56% [1]. Recruitment to clinical trials in people with
advanced disease or in palliative care can be particularly
challenging. For example, a recent systematic review
found the target sample size was only achieved in 36.8%
of trials assessing a therapeutic intervention [2]. Eligibility
can be a major limiting factor affecting recruitment in ad-
vanced disease. Trials often need to screen 10–15 patients
to recruit 1, and strategies to improve recruitment have
had variable success [3–11]. To advance the evidence base
in palliative care we need high-quality clinical trials, in-
cluding Clinical Trials of an Investigational Medicinal
Product, of which there are few, in part due to these
challenges [12].
Retention in clinical trials is perhaps even more im-
portant and has recently been identified as a top priority
[13–15], with high levels of attrition a well-recognised
problem. A review of clinical trials in advanced cancer
identified a median attrition of 26% at the primary end
point, increasing to 44% at the end of the study [16].
Reasons for attrition included a high symptom burden
(21%), patient preference (15%), hospitalisation (10%),
and death (6%) [16]. Attrition can lead to high levels of
missing data, the level of which, in a recent systematic
review of palliative care trials, was associated with study
duration and an increasing number of study question-
naires and/or tests [17]. However, even for palliative care
drug trials of short duration (4 weeks), attrition has been
shown to be high, with only 40% of participants achieving
the primary end point in a trial of pregabalin for cancer-
induced bone pain [5]. A review of 108 RCTs of palliative
care interventions found that the reason for missing data
was unclassified in 53%, recorded as loss to follow-up or
withdrawal with no further details of the underlying
reason [18]. Meta-ethnographic review has identified five
themes which may influence nonretention in trials:
1. Aspects of the trial did not fit with sense of self.
2. The trial design was not individualised.
3. Trial processes were not in line with individual
capabilities.
4. Concerns about the trial medication
5. The extent to which trial participation could be
appropriately accommodated to individuals’ broader
lives [19]
Research within clinical trials units has considered
methods that may improve recruitment and retention,
identifying the importance of support and training for
researchers and clinicians and choice of appropriate out-
come measures [14, 20]. However, strategies to improve
recruitment into trials have had variable success [3].
There is an increasing literature on person-centeredness
in trials, with growing evidence that involving patients at
the research design stage can direct recruitment and
retention strategies and improve enrolment [21–23].
Patient and public involvement (PPI) is one method of
applying person-centeredness to trials and can help to
ensure that the research process is participant-friendly
and trial information is relevant, readable and under-
standable [24, 25]. While studies evaluating person-
centred care in trials remain limited, Chhatre et al. ap-
plied a conceptual model of patient-centred recruitment
and retention to an RCT of patients with newly diag-
nosed prostate cancer [26]. The study identified strat-
egies which may aid recruitment and retention.
However, limitations due to time and resource con-
straints were acknowledged, and attrition was 26% at
one of the three sites [26].
As more people approach the end of their lives with
chronic and complex conditions, the need for robust
research and evidence has never been greater. How-
ever, clinical trials in palliative care remain sparse,
often limited by poor funding and methodological
weaknesses [2, 27, 28]. It is therefore important to
understand what affects retention so that we can minimise
attrition and ensure high-quality clinical trials of palliative
care interventions in the future. We conducted a qualita-
tive study embedded within a randomised feasibility de-
signed using a person-centred approach. The study aimed
to explore what influenced participants to take part and
remain in the trial.
Methods
Design
We conducted a qualitative study embedded within a
randomised trial of mirtazapine for chronic or refractory
breathlessness (BETTER-B[Feasibility]: BETter Treat-
mEnts for Refractory Breathlessness). The trial design
aimed to optimise recruitment and retention through
the use of a person-centred approach, which has been
shown to enable engagement and improve patient out-
comes in advanced disease [29–31].
On the basis of core concepts of person-centred care
described by Kitson et al. [32], and following feedback
from PPI representatives, we developed the model of a
person-centred trial (Fig. 1). Our study design aimed to
put the patient at the centre of the trial and minimise
study burden, thereby enabling participants to be
actively involved and able to participate. The design
focused on developing a genuine relationship between
the researcher and participant, with emphasis on
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continuity. Burden from the trial was minimised by of-
fering home visits and helping participants to complete
trial-related questionnaires to ensure a supportive sys-
tem. PPI contributed to all stages of the trial, from
design to analysis, with representatives on the trial
management group and the trial steering committee.
Trial burden was highlighted as important, and changes
were made to the patient information sheet to ensure a
clearer explanation of trial processes, including the
concept of randomisation.
In-depth interviews were conducted with patients who
had taken part in a double-blind, randomised feasibility
trial of mirtazapine for chronic or refractory breathless-
ness. Ethical approval was received from the UK Health
Research Authority (16/LO/0091), and the trial was
prospectively registered (ISRCTN 32236160). The study
is reported in accordance with the Consolidated Criteria
for Reporting Qualitative Studies (COREQ) [33].
Setting
Participants were recruited from three UK sites: King’s
College Hospital, Nottingham City Hospital NHS Trust,
and Castle Hill Hospital. Potential participants were iden-
tified through inpatient clinical teams, multidisciplinary
team meetings, hospital clinic lists, and hospital databases.
At each site there was a small dedicated research team
who were involved in both the recruitment and follow-up
data collection across all time points of the trial.
Study participants and sampling
Those eligible for the feasibility trial were adults with
cancer, chronic obstructive pulmonary disease (COPD),
interstitial lung disease (ILD), or chronic heart failure
(CHF), with a modified Medical Research Council
(mMRC) dyspnoea scale grade 3 (‘I stop for breath after
walking about 100 yards or after a few minutes on the
level’) or 4 (‘I am too breathless to leave the house’ or ‘I
am breathless when dressing’), with no current diagnosis
of severe depression, and not currently prescribed an
antidepressant medication. For full eligibility criteria see
Appendix 1. A sampling frame was agreed which included
characteristics considered to be important, including gen-
der, diagnosis, trial completion/noncompletion, and age
(< 65 years/> 65 years). However, due to the limited pool
of participants we decided to take a pragmatic approach
and used convenience sampling, offering each trial partici-
pant the opportunity to participate in a qualitative inter-
view. Participants were approached by telephone or in
person to arrange an interview. All participants provided
written informed consent prior to their interview.
Trial schedule
Patients and carers were approached by their usual
clinician and provided with some initial information
about the trial. If they were in agreement, they were then
contacted by a researcher, who was able to provide more
detailed information, including the rationale for doing
Fig. 1 The person-centred trial
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the study, the trial design, and what it would mean if
they agreed to take part in terms of the intervention and
study assessments. All members of the research team
had training and experience of working with people
living with advanced disease. Patients were given a mini-
mum of 24 h to consider the trial and discuss it with
friends and family. Participants then provided written in-
formed consent, and a more detailed eligibility assess-
ment followed. After randomisation, the medication was
provided along with a diary to complete, details of whom
to contact with any questions or concerns, and emer-
gency contact details for out of hours. Participants re-
ceived 28 days of trial treatment (either oral mirtazapine
or placebo capsules). They were assessed face to face on
day 0, day 14, and day 28, and via telephone on day 7,
day 21, and day 35. Assessments were organised at a
time which was convenient for the participant with some
flexibility (± 1 day). Participants were offered to be
visited at home, and assistance was provided with com-
pleting the trial-based questionnaires. Continuity of the
researcher was prioritised where possible.
Data collection
Qualitative interviews were conducted at the end of the
trial. Interviews were conducted in a place of the partici-
pant’s choosing. This was usually their own home, but
some interviews were conducted in hospital. The topic
guide (Appendix 2) was developed using existing litera-
ture and refined following feedback from PPI representa-
tives and the trial management group [1–6]. The
interview schedule included questions about experience
of recruitment to the trial, why they had decided to take
part, expectations of the trial, and experience of trial
processes (taking the trial medication, experience of trial
visits, and experience of completing the trial question-
naires). Interviews were digitally audio recorded and
transcribed verbatim. A distress protocol was used to
minimise the risk of potential harm. All interviews were
conducted by one female researcher (NL) with a medical
background, who had completed training in in-depth
interviewing. Interviews took place between January
2017 and December 2017.
Analysis
The qualitative interviews were analysed using Braun
and Clarke’s framework for thematic analysis [29] using
NVivo version 10 software (QSR International UK Ltd.,
Warrington, UK). Transcripts were read and re-read and
then coded inductively for themes relating to reasons to
participate in the trial, reasons not to participate in the
trial, reasons to remain in the trial and reasons to dis-
continue the trial. Results were considered in relation to
the core elements of person-centred care and our model
of the person-centred trial (Fig. 1) [32]. Three transcripts
were double-coded by another researcher (SNE), who
produced their own coding frame. Areas of agreement
and disagreement were then discussed until consensus
was achieved.
Results
The feasibility trial was open to recruitment between
August 2016 and November 2017. Each centre was open
for a total of 12 months. A total of 409 patients were
screened; 150 were eligible, and 64 were randomised. No
participants were lost to follow-up. Twelve participants
discontinued treatment prior to day 28, five of whom
withdrew from data collection. Forty participants (63%)
required some help competing the trial questionnaires.
The qualitative interviews were conducted between
January 2017 and December 2017. The median time
between trial completion and qualitative interview was
83 days (range 1–252). Twenty-two participants were
interviewed. Eleven had a diagnosis of COPD, 8 ILD, 2
CHF and 1 lung cancer. The median age was 71 years
(range 56–84). Sixteen were male. Twenty had com-
pleted the trial, whilst two withdrew due to reported ad-
verse effects of the trial medication. The mean interview
duration was 33min (range 15–104). Despite the use of
convenience sampling, variation was achieved, and we
interviewed participants from all three research sites, all
disease groups, both age and gender categories, with two
non-completers also participating in interviews. No trial
decliners agreed to complete a qualitative interview
(Table 1).
The relationship between patient and professional,
potential for benefit, trial processes and the intervention
all influenced the decision to participate in the trial. The
relationship and continuity with the research team,
Table 1 Characteristics of participants
Male Female
ILD
< 65 years old 1
> 65 years old 5 3a
COPD
< 65 years old 2 1
> 65 years old 5 1
CHF
< 65 years old
> 65 years old 2a
Cancer
< 65 years old
> 65 years old 1 1
Abbreviations: CHF congestive heart failure, COPD chronic obstructive
pulmonary disease, ILD interstitial lung disease
aOne did not complete trial
Lovell et al. Trials          (2020) 21:215 Page 4 of 13
perceived benefit, and aspects relating to trial processes
and the intervention influenced the decision to remain
in the trial.
What influenced people to take part in the trial
Approach
The way in which potential participants were approached
was important when considering whether to take part in
the trial. Many chose to participate because of their rela-
tionship with their usual clinician. Being approached by
someone familiar appeared to validate the authenticity of
the trial. A genuine patient–professional relationship
based on open communication, knowledge and skills was
valued and made patients more likely to agree to be con-
tacted by a researcher.
‘It came through when I was at the IPF meeting and
my consultant was there that day giving a talk so I
figured it was bona fide’. − 1010, female with ILD >
65 years old
‘My doctor said ‘well try it, anything’s worth a try’.
It’s our GP… we’ve known him for a while… he’s a
doctor that listens to you.… He’s very good like’. −
1022, male with COPD > 65 years old
The initial encounter with the researcher was key.
Clear communication of trial-related material estab-
lished confidence in the research team. Despite some
participants having concerns about the expectation that
might be placed on them, they felt reassured when the
initial assessment was tailored and focused to their indi-
vidual needs (e.g., by ensuring that the participant did
not feel rushed, and helping them to complete the trial
questionnaires). Fundamental was the ability of the
researcher to assess and meet these individual needs:
‘The interviewers were very pleasant, very helpful,
they explained everything to me, and I agreed to it’.
– 1001, male with COPD > 65 years old
‘I thought, I hope they’re not going to push me too
much … but everything was fine, you know, spot on.
They understood my needs. People took the time
and they listen to you’. – 1014, male with COPD
< 65 years old
Motivations to take part
The possibility of potential benefit was a large contribut-
ing factor when deciding whether to participate in the
trial. Most commonly participants described hoping for
an improvement in symptoms, above all their breathing.
Many viewed the trial as an opportunity to have extra in-
put from clinical services, including additional assessments
prior to enrolment, regular monitoring throughout the trial,
and being seen by a specialist.
‘I was prepared to try anything that would help
with me breathing’. – 1015, female with COPD
> 65 years old
‘I had a full medical before I started on the course,
which was good, it eased my mind’. – 1015, female
with COPD > 65 years old
‘They just told us that we would be regularly
monitored’. – 1010, female with ILD > 65 years old
‘It opens doors at the hospitals for you, like I’ve got
to see a specialist through it’. – 1022, male with
COPD > 65 years old
For many, living with chronic or refractory breathless-
ness can be an isolating experience, and therefore the
social aspect of participating in the trial was perceived as
a potential benefit, with the trial providing an opportun-
ity to meet other people who were in a similar position.
‘I was gonna gain in that I would be meeting a few
more people’. – 1009, male with COPD > 65 years
old
Participants appeared to understand the concept of
randomisation and were mostly accepting of the fact that
they may not receive the active medication. However,
some participants did express concerns about receiving
the placebo medication and missing out on a potential
benefit from the active medication.
‘I just sort of tried to take it in my stride, whichever I
get, I get, cause there’s not a lot you can do about it’.
– 1001, male with ILD > 65 years old
‘Only if it wasn’t the drug … then there might not be
a chance of it working’. – 1008, male with ILD < 65
years old
Altruism was also commonly described, and people
wanted to participate to help others, regardless of
whether they would experience a direct benefit. One
man with COPD explained that he did not expect the
trial to help him but hoped it might benefit others in the
future. Participants also talked about their individual
experience of receiving healthcare, often over a number
of years, and many felt that the trial was an opportunity
to be involved and give something back to the health
service. Some people recognised the importance of
clinical trials in the context of research and wanted to
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participate to advance science and help to develop new
treatments.
‘It won’t do me any good but it might help other
people in the future, you know. So, my expectations
are in the ways that it’ll help other people in the
future, you know, by me taking a part in these trials’.
– 1014, male with COPD < 65 years old
‘I have had some wonderful service from the NHS
[National Health Service], and I thought well this is
a chance to pay something back by taking part’. –
1004, male with COPD > 65 years old
‘People need to know about these things…. If it is
going to help then I’ll take part in these trials. To,
you know, help, help science’. – 1005, male with ILD
> 65 years old
Trial design and the intervention
The trial design was important when deciding whether
to participate and attempts to minimise burden were
viewed favourably by participants. The opportunity to be
visited at home instead of going into hospital was a posi-
tive influence and made people more likely to participate
in the trial.
‘I didn’t have to go to the hospital…. You do home
visits, and that, that made my mind up even more
to do it. Because of the struggling to walk and
everything else, so I was more than happy’. –
1003, male with COPD > 65 years old
The intervention was perceived as simple and low risk,
and for some it was important that they could continue
other disease-specific medications but still be part of the
trial.
‘The taking of the medication was simple, I didn’t forget
it once’. – 1004, male with COPD > 65 years old
‘I rang up the hospital and asked, and they said,
‘Yeah, you’ll be ok, ones for your brain and ones for
your lungs’. – 1010, female with ILD > 65 years old
Whilst some participants expressed concerns about
taking an antidepressant medication, this was mostly off-
set by implicit trust in the clinicians and researchers,
and a belief that they wouldn’t be given anything which
could cause harm.
‘That was my thought when they first said anti-
depressant, ‘Oh, do I want to be taking something
like that?’ But at the end of the day, they’re not going
to do anything that’s going to put you at any risk’. –
1020, male with COPD < 65 years old
Although we only interviewed people who had partici-
pated in the trial, the interviews did highlight some con-
cerns relating to the intervention. One participant who
experienced adverse effects and later withdrew from the
trial felt that more information could have been pro-
vided about the trial medication.
‘It wasn’t a great deal of information about the
actual drug, to be honest’. – 1016, male with heart
failure > 65 years old
What influenced people to remain in the trial
Importance of the relationship and continuity of care
The importance of the relationship between the partici-
pant and the researcher was identified across all inter-
views and was substantial when considering the reasons
why people remained in the trial. Attempts by the re-
searcher to minimise burden and ensure a calm environ-
ment were recognised and appreciated by participants.
The personal attributes of the researcher were also cen-
tral to remaining in the trial. Participants described the
importance of effective communication, being treated
with respect, and not feeling rushed during trial visits.
‘I found the people extremely helpful; nothing was
too much trouble. Everything was explained in
meticulous detail really, it was so easy, everything
was done for you, the drugs were all measured out
you had the right number for the right days. All I
had to do was wake up and pop the pill, you know.
The people were lovely, it was a very, very rewarding
experience in a lot of ways’. – 1020, male with
COPD < 65 years old
‘Like [the research nurse] said, if there’s any problems
and you can’t make it, just give us a ring or anything
like that, there’s no, you must arrive or that sort of
thing. And it’s a relaxing place, when you go there,
there’s no hustle and bustle’. – 1013, male with
COPD > 65 years old
‘The [research nurses] are absolutely brilliant, and
that does make a difference, you know that you’re
going to walk in.… They explain things so well don’t
they, and they’re so patient and you know’. – 1012,
male with ILD > 65 years old
‘They ask you a question, but they listen to you, they
didn’t jump in and try to answer for you. I was
number one, you know what I mean’. – 1014,
male with COPD < 65 years old
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Continuity was important and enabled participants to
build up a relationship with the research team. One
participant explained that while they did not always see
the same member of the research team, someone they
had met before always made an effort to come and say
hello when they arrived.
‘I’d go in and sit down, they’d maybe make me a cup
of tea if I was waiting and whatever, then they’d
come through. It wasn’t always the same person, but
[research nurse] would pop in and say hello and
she’d say so-and-so’s seeing you today’. – 1020, male
with COPD < 65 years old
In contrast, not being given clear trial-related infor-
mation and feeling rushed by members of the re-
search team was reported by one participant who
chose to withdraw from the trial. While the partici-
pant chose to withdraw due to adverse effects of the
trial medication, these other factors may have contrib-
uted to this decision.
‘It was a bit rushed wasn’t it’? – 1016, male with
heart failure > 65 years old
Perceived benefits
Perceived benefits from the trial medication moti-
vated people to remain in the trial. Participants de-
scribed improved breathing but also beneficial effects
on sleep, fatigue and appetite, which for some led to
increased confidence and an ability to be more ac-
tive. Participants also perceived the regular monitor-
ing they received during the trial to be beneficial
and describing feeling ‘taken care of’ during the trial
period.
‘Everything was so much better. I would sleep
better, so if I sleep better that means by
breathing is better when I wake up in the morning,
which it never was before. Everything has just
changed for the better’. – 1003, male with COPD
> 65 years old
‘The follow-up has been very good. I was seen at
weekly intervals to see how things were progressing,
and if there were any problems, so I felt I was being
taken care of in terms of the trial’. – 1017, male with
ILD > 65 years old
The social aspect was an additional benefit for many
participants and provided an interruption to an other-
wise sometimes isolating existence. This was described
by participants visited at home but also by those who
were reviewed in the clinical trials unit.
‘I quite enjoyed the experience of having somebody
to come in and talk to me’. – 1001, male with
ILD > 65 years old, visited at home
‘They could’ve come to my home, but I prefer to
come here ’cause it gets me out the house for an hour
or two…. It’s nice just to come somewhere and, as I
say, meet different people, see different people, which
is half the battle when you, you know’. – 1014, male
with COPD < 65 years old, attended the trials unit
It was important that participants felt actively involved
and as though they were contributing to the trial. Know-
ing that the trial may benefit patients in the future, as
well as providing an opportunity for individuals to give
back were motivating factors for completing the trial.
Several participants described how they found the trial
process rewarding on an individual level.
‘I just felt as though I was doing some good. It was
personally rewarding for me, because I felt as though
I was contributing, you know’. – 1020, male with
COPD < 65 years old
Trial processes and the intervention
Aspects relating to the trial design and intervention were
also important when considering the reasons why partic-
ipants remained in the trial. The offer of home visits re-
duced the burden of participating, and while participants
described the questionnaires as straightforward, they
were grateful when help was provided.
‘Being at home was perfect, they were always on
time, and prompt. Oh the home visits are quite good
you know. Saved me a lot of bother not going to the
hospital’. – 1002, male with COPD > 65 years old
‘If there were any problems, then they would run
me through the questions’. – 1020, male with
COPD < 65 years old
The intervention was simple and well tolerated, and
participants found the chart provided a useful reminder.
Trial duration was also important, with a shorter dur-
ation felt to be more manageable.
‘It was tablets and I took them every day as I was
asked to, um, we made a note of them in a chart to
make sure I had taken them, it was no problem at
all’. – 1001, male with ILD > 65 years old
‘I thought that as it was also only over a 28-day
period, I thought, yeah, I’d, I’d be quite happy to try’.
– 1010, female with ILD > 65 years old
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Adverse effects of the intervention were an important
influence for participants discontinuing the trial and
were reported by both participants who were inter-
viewed after withdrawing from the trial.
‘I just sat up in bed looking at the tablets and thinking,
should I chance it tonight or not, because I knew how I
might feel a bit groggy the next day, so it put
you off taking the tablet’. – 1019, female with
ILD > 65 years old
Discussion
This study identifies important considerations which
may influence recruitment and retention in clinical
trials. We found that the relationship between patient
and professional, potential for benefit, trial processes
and the intervention all influenced the decision to par-
ticipate in the trial. The relationship with the research
team and continuity, perceived benefit, and aspects relat-
ing to trial processes and the intervention influenced the
decision to remain in the trial. In this trial recruitment
targets were met and attrition levels were low, suggest-
ing that a person-centred approach can support success-
ful recruitment and retention.
What influences potential participants to take part in a
clinical trial (or not) is recognised to be a complex
multifactorial process [34–39]. In this study we found
that the initial approach by both clinician and researcher
was key in developing a genuine relationship built on
trust, a concept which has been identified as important
when deciding whether to participate in a clinical trial
[34, 35, 40]. In this study participants described the po-
tential benefit to self and others as a motivating factor,
comparable to the findings of previous qualitative re-
search conducted in the palliative care setting [37].
While concerns about randomisation and the potential
for side effects can be deterrents to participating in a
clinical trial [36], this was not a major influencing factor
for the participants we interviewed. The trial design was
important, and attempts to minimise burden were
viewed favourably by participants. This is an important
consideration as missing data in trials has been shown to
increase with the number of questionnaires/tests [17].
In this study the relationship between the patient and
professional was crucial, and particularly important
when considering what influenced people to remain in
the trial. Feeling listened to, being treated with respect,
and having their needs understood were important influ-
ences supporting retention. The continuity of the re-
search team was also important and enabled participants
to build up a trusting relationship over the trial duration;
one participant referred to this as ‘feeling like part of the
family’. In addition, participants praised the research
team for the extra time taken during trial visits. This
ensured that individuals did not feel rushed and allowed
assessments to be completed in the participant’s own
time. These findings have implications for the set-up of
research teams across trials. While our results highlight
the importance of developing a genuine patient–profes-
sional relationship, this needs to be balanced so that
patients do not feel coerced to take part or remain in a
trial. Training and the use of standard operating proce-
dures are also crucial to ensure that assistance with
questionnaires is applied in a consistent manner. Al-
though there are often concerns about including people
with advanced disease in studies, research suggests that
those living with advanced disease want the opportunity
to be involved in research and report it to be a positive
experience from which they benefit [41].
The trial design and trial processes were also import-
ant considerations, particularly for trial retention. It has
been suggested that an individualised design, based on
individual capabilities, which enables participation along-
side the other challenges in life, may have a positive im-
pact on trial retention [19]. We applied a person-centred
approach by providing clear trial-related information, of-
fering home visits, involving the carer, and assisting with
trial-related questionnaires. PPI was crucial, and feedback
from representatives ensured that that the trial worked
around the patient and not the other way around.
The results of this study have important implications
for policy and funding. In our trial, a small, dedicated re-
search team facilitated a genuine relationship based on
open communication, knowledge and the perceived skill
set of the researcher. Home visits and spending time
with the participant, often helping them to complete
trial questionnaires (63% of participants in this trial),
was important. Time and resource constraints have been
acknowledged as limitations in other studies, and if we
are to improve retention within trials, we need to ensure
that funding allows adequate resource allocation to
spend time supporting participants with trial processes
[26]. While our study suggests a benefit to having the
same researchers working across all stages of a trial,
current funding models in the United Kingdom focus
specifically on recruitment and not on retention, and
therefore the funding for follow-up often needs to be
pooled from other budgets [42]. In practice, continuity
of research staff is not a commonly reported outcome,
and so it is difficult to know the impact of this across
different specialties and for larger trials. To ensure that
the same researchers are able to work across trials, fund-
ing models need to be revised to rebalance of emphasis
of recruitment and retention [43].
It is important to acknowledge that the researchers in
our trial all had training and experience in working with
people living with advanced disease. Participants valued
the personal attributes of the professional, a quality
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which has been identified as critical in person-centred
care [32]. Characteristics which have previously been iden-
tified as important for palliative care professionals include
interpersonal skills, a willingness to listen, being someone
the patient feels able to talk to, demonstrating an interest
in knowing patients as people, and recognising that
patients may need to feel in control [32, 44]. Therefore,
the attributes of professionals delivering person-centred
care and palliative care are closely aligned [45]. Increased
opportunities for the training of research staff has been
highlighted as important if we are to improve retention in
clinical trials in the future [20, 43].
How can person-centred care be applied to clinical trials
in practice?
To improve retention, clinical trials need to be individua-
lised, with processes in line with individual capabilities, and
considered alongside the other challenges in life [19]. We
propose that implementing a person-centred approach can
support recruitment and retention. Our model focuses on
three key areas: development of a genuine relationship be-
tween the participant and professional, enabling participa-
tion, and ensuring that trial processes are person-centred
(Fig. 2). Education and training can help to provide profes-
sionals with the required knowledge and skill set and en-
sure that trial assessments are tailored to the holistic needs
of the individual. Continuity of the research team provides
an opportunity for the researcher and participant to build a
genuine relationship during the trial period. Person-centred
trial processes such as home visits and helping participants
to complete trial-related questionnaires help to minimise
the burden for participants.
Strengths and limitations
To our knowledge, this is the first study to consider what
influences people to take part and, more importantly, re-
main in a clinical trial in the context of advanced disease.
The study used in-depth interviews, and despite the use of
convenience sampling, achieved variation with participants
across all characteristics identified to be important. While a
single researcher conducted all of the interviews, interpret-
ation bias was minimised by use of a reflexive diary,
double-coding of a subset of transcripts, and discussion of
findings within the research team.
The study was limited by one female researcher (NL)
with a medical background conducting all of the inter-
views. In addition, some of the interviewees had met this
researcher during the feasibility trial, thereby increasing
the risk of social desirability bias, and participants may
have been reluctant to offer criticisms about the trial
intervention and/or processes. The time period between
the trial ending and a qualitative interview being
Fig. 2 The person-centred trial in practice
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conducted varied, and this may have increased the risk
of recall bias in the qualitative interviews. Some inter-
views were conducted with a carer present, which may
have impacted the answers given. Although we achieved
a varied sample of trial participants, we only interviewed
two participants who did not complete the trial, and we
were not able to interview anyone who declined to
participate in the trial.
The trial itself was of short duration with an arguably
simple intervention and may therefore be perceived as
easier in terms of recruitment and retention than a lon-
ger trial or one of a complex intervention. However,
challenges with recruitment (in part due to eligibility)
and high attrition levels have previously been demon-
strated in short-duration drug trials conducted in people
with advanced disease [5]. Sixteen of the interviews were
conducted with male patients, which is reflective of the
main trial participants. This is similar to other trials [46]
and may reflect the fact that chronic lung disease has
previously been considered to be a condition predomin-
antly affecting men [47]. It has recently been acknowl-
edged, however, that women remain underrepresented
in chronic lung disease trials, and this should be ad-
dressed in future research [48]. With an aging popula-
tion, an increasing number of people are living with
chronic and complex conditions and multimorbidity.
The findings of our study are therefore relevant and im-
portant for clinical trials in the future.
Conclusions
This study identifies important considerations which influ-
enced the decision to participate and remain in a feasibility
trial of mirtazapine for chronic or refractory breathlessness.
Results should be considered within the context of the
existing literature, which suggests an increasing role for a
person-centred approach in trials. PPI can help to identify
how aspects of a trial can be more person-centred and
should be incorporated at all stages of trial design. We
propose that prioritisation of the relationship between the
patient and the professional, ensuring the trial design is as
person-centred as possible, and enabling people to partici-
pate with processes in line with individual capabilities may
improve recruitment and retention in clinical trials in
advanced disease. The results of this study have potential
implications for the future funding of trials and highlight
the importance of having a dedicated research team who
are able to build a genuine relationship with participants
throughout the duration of a trial. Our model of the
person-centred trial should be considered when designing a
clinical trial, ideally at the prefunding stage and involving
PPI representatives across all stages of trial development
and analysis. Future work should aim to evaluate the appli-





1. Male or female aged ≥ 18 years old
2. Diagnosed with cancer, COPD, ILD or chronic
heart failure (New York Heart Association class III
or IV)
3. Breathlessness severity: mMRC dyspnoea scale
grade 3 or 4
4. Receiving optimal treatment of the underlying
condition in the opinion of the identifying clinician
5. Management of the underlying condition has
remained unchanged for the previous 1 week
6. Reversible causes of breathlessness optimally treated
in the opinion of the identifying clinician
7. Expected prognosis ≥ 2 months
8. If female and of child-bearing potential, agrees to
use adequate contraception
9. Able to complete questionnaires and trial assessments
10. Able to provide written informed consent
Exclusion criteria:
1. Existing antidepressant use
2. Known contraindication to mirtazapine
3. Hypersensitivity to the active substance or to any of
the components of the mirtazapine or placebo (e.g.,
lactose intolerance)
4. Australia modified Karnofsky Performance Status
score ≤ 40
5. Pregnant or breast-feeding women
6. Patients with acute cardiac events within 3 months
of randomisation (myocardial infarction, unstable
angina pectoris or significant cardiac conduction
disturbance)
7. Patients with known hepatic impairment
8. Patients with known renal impairment
9. Patients with uncontrolled blood pressure
10. Patients with uncontrolled diabetes mellitus
11. Patients with uncontrolled seizures, epilepsy or
organic brain syndrome
12. Patients with severe depression or suicidal thoughts
13. Patients with a history of psychotic illness
(schizophrenia, bipolar disorder, mania, hypomania




You have recently taken part in a study called Better
B. I would like to talk to you to understand your experi-
ence of taking part, what you expected, and what it was
like.
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If you want to stop the interview at any point, let me
know. You don’t need to give a reason, and your clinical
care won’t be affected. Everything you say will be kept
confidential.
Do you have any questions before we begin?
Introduction/Better-B
What did you understand about the study?
What was your experience of taking part?
Prompt: Can you tell me a bit about that?
Recruitment/joining the study
How were you asked to take part in the study?
What was that like?
Prompt: Who spoke to you? What were you told?
Where were you at the time?
What were your expectations?
Why did you decide to take part?
Prompt: What specifically did you want to see
improved? What changes were you hoping for?
Trial processes/taking part
What did you understand about the treatment you
received?
Prompt: What did you think about taking an anti-
depressant medication? What do you understand about
a placebo drug/randomisation?
How did you find taking the medication?
Probe: Did you have any difficulties? How did you
manage with your other medications? (dosette box/blister
pack/diary as reminder).
How did you like being visited at home?
Would you have preferred to have been seen some-
where else?
How did you find it completing the questionnaires?
Probe: What did you think about the questions we
asked? Do you think they were the right questions? Did
they capture what is important to you?
Would anything have made it easier to take part?
Probe: What were the downsides to taking part?
Change
Tell me in what ways the drug changed how you felt?
Prompt: Did you notice any change in your breathing,
sleep, appetite, drowsiness?
What did you hope would change?
For you, what would be the most important change?
Were there any changes you had not expected?
Closing section
Is there anything else that you think is important for
me to know?
Is there anything that has worried you during the
course of this conversation?
Is there anything else you would like to talk about?
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